Aspen Pharmacare Holdings Stock Forecast for 2023 - 2025 - 2030

Updated on 03/28/2024

Stock Rating
18
Price Target
R219.00
Consensus
Outperform
Upside
6.36%
Analysts
1
Stock Rating
18
Upside
6.36%
Analysts
1
Price Target
R219.00

Aspen Pharmacare Holdings Stock Forecast and Price Target

The average price target for Aspen Pharmacare Holdings's stock set by recognized analysts recently is R219.00, which would result in a potential upside of approximately 6.36% if it reached this mark. The estimation is based on a high estimate of R233.27 and a low estimate of R211.00. If you are looking to invest in the stock, it's important to research and compare different companies.

R219.00

6.36% Upside

Outperform
Outperform

Aspen Pharmacare Holdings Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Aspen Pharmacare Holdings's Price has seen a drop from R159.10 to R0.00 – a 100.00% decrease. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach R171.59 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for Aspen Pharmacare Holdings will be 100.00%.

2024 Fair Value Forecast
R171.59
2025 Fair Value Forecast
R204.28
2026 Fair Value Forecast
R223.50
2027 Fair Value Forecast
R130.67
2028 Fair Value Forecast
R150.90
2029 Fair Value Forecast
R175.57
2030 Fair Value Forecast
R201.08
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
SUNPHARMA Stock Forecast Sun Pharmaceutical Industries Outperform 8
Rp1.59k Buy/Sell Rp1.52k -1.42%
TEVA Stock Forecast Teva Pharmaceutical Industries Outperform 12
$13.35 Buy/Sell $11.59 19.85%
VTRS Stock Forecast Viatris Inc Hold 8
$11.97 Buy/Sell $11.73 0.25%
SHP Stock Forecast Shoprite Holdings Ltd Hold 18
R268.84 Buy/Sell R267.29 4.15%
HIK Stock Forecast Hikma Pharmaceuticals PLC Outperform 18
£19.10 Buy/Sell £28.11 55.34%

Aspen Pharmacare Holdings Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Revenue for Aspen Pharmacare Holdings has grown by 5.34%, going from R38.65B to R40.71B. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach R44.82B – an increase of 10.11%. Over the next seven years, experts anticipate that Revenue growth for Aspen Pharmacare Holdings will be 21.50%.

2024 Rev Forecast
R44.82B
2025 Rev Forecast
R49.31B
2026 Rev Forecast
R52.44B
2027 Rev Forecast
R48.20B
2028 Rev Forecast
R47.19B
2029 Rev Forecast
R47.97B
2030 Rev Forecast
R49.46B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
RICHTER Stock Forecast Outperform 18
Ft9.66k Buy/Sell Ft11.02k 20.86%
KRKG Stock Forecast Krka, d. d. Buy 18
123.00€ Buy/Sell 119.80€ 15.85%
PRGO Stock Forecast Perrigo Co PLC Outperform 16
$30.59 Buy/Sell $44.75 27.49%

Aspen Pharmacare Holdings Dividend per Share Forecast for 2023 - 2025 - 2030

Aspen Pharmacare Holdings's Dividend per Share has grown in the last two years, jumping from R2.62 to R3.42 – an increase of 30.53%. In the next year, analysts predict that Dividend per Share will reach R3.61 – an increase of 5.56%. For the next seven years, the forecast is for Dividend per Share to grow by 31.49%.

2024 DPS Forecast
R3.61
2025 DPS Forecast
R4.19
2026 DPS Forecast
R5.06
2027 DPS Forecast
R4.45
2028 DPS Forecast
R4.19
2029 DPS Forecast
R4.23
2030 DPS Forecast
R4.50

Aspen Pharmacare Holdings Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
R0.07B
2025 FCF Forecast
R7.08B
2026 FCF Forecast
R10.55B
2027 FCF Forecast
R4.75B
2028 FCF Forecast
R4.60B
2029 FCF Forecast
R6.01B
2030 FCF Forecast
R8.05B

Aspen Pharmacare Holdings EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Aspen Pharmacare Holdings's EBITDA has decreased from R10.43B to R10.19B – a 2.31% drop. For next year, the 5 analysts predict EBITDA of R11.61B, which would mean an increase of 13.92%. Over the next seven years, the pros' prediction is EBITDAof R13.24B, which would mean a seven-year growth forecast of 29.97%.

2024 EBITDA Forecast
R11.61B
2025 EBITDA Forecast
R13.41B
2026 EBITDA Forecast
R14.19B
2027 EBITDA Forecast
R12.72B
2028 EBITDA Forecast
R12.41B
2029 EBITDA Forecast
R12.76B
2030 EBITDA Forecast
R13.24B

Aspen Pharmacare Holdings EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Aspen Pharmacare Holdings's EBIT has decreased by 4.75%, going from R9.37B to R8.93B. In the next year, analysts expect EBIT to reach R9.64B – an increase of 7.99%. For the next eight years, the forecast is for EBIT to grow by 26.76%.

2024 EBIT Forecast
R9.64B
2024 EBIT Forecast
R9.64B
2025 EBIT Forecast
R11.36B
2026 EBIT Forecast
R12.07B
2027 EBIT Forecast
R11.22B
2028 EBIT Forecast
R10.72B
2029 EBIT Forecast
R10.95B
2030 EBIT Forecast
R11.32B

Aspen Pharmacare Holdings EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Aspen Pharmacare Holdings's EPS has seen a drop from R14.65 to R0.00 – a 100.00% decrease. In the coming year, analysts are expecting an increase in EPS, predicting it will reach R15.80 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for Aspen Pharmacare Holdings will be 100.00%.

2024 EPS Forecast
R15.80
2025 EPS Forecast
R18.81
2026 EPS Forecast
R20.58
2027 EPS Forecast
R12.03
2028 EPS Forecast
R13.90
2029 EPS Forecast
R16.17
2030 EPS Forecast
R18.52